These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

165 related items for PubMed ID: 38552315

  • 1. Long-term efficacy and safety of subcutaneous tocilizumab in clinical trials of polyarticular or systemic juvenile idiopathic arthritis.
    Brunner HI, Ruperto N, Ramanan AV, Horneff G, Minden K, Calvo Penades I, Alexeeva E, Cleary G, Stern SM, Kone-Paut I, Maldonado Velázquez MDR, Rabinovich CE, Remesal A, Silva CA, Nikishina I, Zucchetto M, Brockwell L, Gordon O, Nagel S, De Benedetti F, PRINTO and PRCSG Investigators.
    Rheumatology (Oxford); 2024 Sep 01; 63(9):2535-2546. PubMed ID: 38552315
    [Abstract] [Full Text] [Related]

  • 2. Subcutaneous dosing regimens of tocilizumab in children with systemic or polyarticular juvenile idiopathic arthritis.
    Ruperto N, Brunner HI, Ramanan AV, Horneff G, Cuttica R, Henrickson M, Anton J, Boteanu AL, Penades IC, Minden K, Schmeling H, Hufnagel M, Weiss JE, Pardeo M, Nanda K, Roth J, Rubio-Pérez N, Hsu JC, Wimalasundera S, Wells C, Bharucha K, Douglass W, Bao M, Mallalieu NL, Martini A, Lovell D, Benedetti F, Paediatric Rheumatology INternational Trials Organisation (PRINTO) and the Paediatric Rheumatology Collaborative Study Group (PRCSG).
    Rheumatology (Oxford); 2021 Oct 02; 60(10):4568-4580. PubMed ID: 33506875
    [Abstract] [Full Text] [Related]

  • 3. Long-term, interventional, open-label extension study evaluating the safety of tocilizumab treatment in patients with polyarticular-course juvenile idiopathic arthritis from Poland and Russia who completed the global, international CHERISH trial.
    Opoka-Winiarska V, Żuber Z, Alexeeva E, Chasnyk V, Nikishina I, Dębowska G, Smolewska E.
    Clin Rheumatol; 2018 Jul 02; 37(7):1807-1816. PubMed ID: 29654485
    [Abstract] [Full Text] [Related]

  • 4. Intravenous dosing of tocilizumab in patients younger than two years of age with systemic juvenile idiopathic arthritis: results from an open-label phase 1 clinical trial.
    Mallalieu NL, Wimalasundera S, Hsu JC, Douglass W, Wells C, Penades IC, Cuttica R, Huppertz HI, Joos R, Kimura Y, Milojevic D, Rosenkranz M, Schikler K, Constantin T, Wouters C.
    Pediatr Rheumatol Online J; 2019 Aug 22; 17(1):57. PubMed ID: 31438986
    [Abstract] [Full Text] [Related]

  • 5. Safety of tocilizumab in the treatment of juvenile idiopathic arthritis.
    Machado SH, Xavier RM.
    Expert Opin Drug Saf; 2017 Apr 22; 16(4):493-500. PubMed ID: 28277841
    [Abstract] [Full Text] [Related]

  • 6. Clinical pharmacology of tocilizumab for the treatment of polyarticular-course juvenile idiopathic arthritis.
    Zhang X, Chen YC, Terao K.
    Expert Rev Clin Pharmacol; 2017 May 22; 10(5):471-482. PubMed ID: 28293968
    [Abstract] [Full Text] [Related]

  • 7. Tocilizumab for juvenile idiopathic arthritis: a single-center case series.
    Yazılıtaş F, Özdel S, Şimşek D, Aydoğ Ö, Çakıcı EK, Can GG, Güngör T, Bülbül M.
    Sao Paulo Med J; 2019 May 22; 137(6):517-522. PubMed ID: 32159638
    [Abstract] [Full Text] [Related]

  • 8. Efficacy and Safety of Tocilizumab for Polyarticular-Course Juvenile Idiopathic Arthritis in the Open-Label Two-Year Extension of a Phase III Trial.
    Brunner HI, Ruperto N, Zuber Z, Cuttica R, Keltsev V, Xavier RM, Burgos-Vargas R, Penades IC, Silverman ED, Espada G, Zavaler MF, Kimura Y, Duarte C, Job-Deslandre C, Joos R, Douglass W, Wimalasundera S, Bharucha KN, Wells C, Lovell DJ, Martini A, de Benedetti F, Paediatric Rheumatology International Trials Organisation (PRINTO) and the Pediatric Rheumatology Collaborative Study Group (PRCSG).
    Arthritis Rheumatol; 2021 Mar 22; 73(3):530-541. PubMed ID: 32951358
    [Abstract] [Full Text] [Related]

  • 9. Efficacy and safety of tocilizumab in Chinese patients with systemic juvenile idiopathic arthritis: a multicentre phase IV trial.
    Li C, Tang X, Zhou Z, Sun L, Lu M, Zhou W, Yang S, Zheng W, Yu H, Tan W, Zhang J, Zhang Y, Kong Y, Xu J.
    Clin Rheumatol; 2024 Nov 22; 43(11):3457-3467. PubMed ID: 39279018
    [Abstract] [Full Text] [Related]

  • 10. Longterm safety and effectiveness of the anti-interleukin 6 receptor monoclonal antibody tocilizumab in patients with systemic juvenile idiopathic arthritis in Japan.
    Yokota S, Imagawa T, Mori M, Miyamae T, Takei S, Iwata N, Umebayashi H, Murata T, Miyoshi M, Tomiita M, Nishimoto N, Kishimoto T.
    J Rheumatol; 2014 Apr 22; 41(4):759-67. PubMed ID: 24634205
    [Abstract] [Full Text] [Related]

  • 11. Tocilizumab: a review of its use in the treatment of juvenile idiopathic arthritis.
    Frampton JE.
    Paediatr Drugs; 2013 Dec 22; 15(6):515-31. PubMed ID: 24155139
    [Abstract] [Full Text] [Related]

  • 12. Neutropenia During Tocilizumab Treatment Is Not Associated with Infection Risk in Systemic or Polyarticular-course Juvenile Idiopathic Arthritis.
    Pardeo M, Wang J, Ruperto N, Alexeeva E, Chasnyk V, Schneider R, Horneff G, Huppertz HI, Minden K, Onel K, Zemel L, Martin A, Koné-Paut I, Siamopoulou-Mavridou A, Silva CA, Porter-Brown B, Bharucha KN, Brunner HI, De Benedetti F, Paediatric Rheumatology International Trials Organisation (PRINTO) and the Pediatric Rheumatology Collaborative Study Group (PRCSG).
    J Rheumatol; 2019 Sep 22; 46(9):1117-1126. PubMed ID: 30824645
    [Abstract] [Full Text] [Related]

  • 13. Long-term safety and efficacy of weekly subcutaneous tocilizumab monotherapy in patients with rheumatoid arthritis who had an inadequate response to subcutaneous tocilizumab every other week: Results from the open-label extension of the SHINOBI study.
    Ogata A, Tanaka Y, Ishii T, Kaneko M, Miwa H, Ohsawa S, Yamakawa R, SHINOBI Study Group.
    Mod Rheumatol; 2019 Sep 22; 29(5):767-774. PubMed ID: 30299202
    [Abstract] [Full Text] [Related]

  • 14. Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomised, double-blind withdrawal trial.
    Brunner HI, Ruperto N, Zuber Z, Keane C, Harari O, Kenwright A, Lu P, Cuttica R, Keltsev V, Xavier RM, Calvo I, Nikishina I, Rubio-Pérez N, Alexeeva E, Chasnyk V, Horneff G, Opoka-Winiarska V, Quartier P, Silva CA, Silverman E, Spindler A, Baildam E, Gámir ML, Martin A, Rietschel C, Siri D, Smolewska E, Lovell D, Martini A, De Benedetti F, Paediatric Rheumatology International Trials Organisation PRINTO, Pediatric Rheumatology Collaborative Study Group (PRCSG).
    Ann Rheum Dis; 2015 Jun 22; 74(6):1110-7. PubMed ID: 24834925
    [Abstract] [Full Text] [Related]

  • 15. Safety and efficacy of tocilizumab, an anti-IL-6-receptor monoclonal antibody, in patients with polyarticular-course juvenile idiopathic arthritis.
    Imagawa T, Yokota S, Mori M, Miyamae T, Takei S, Imanaka H, Nerome Y, Iwata N, Murata T, Miyoshi M, Nishimoto N, Kishimoto T.
    Mod Rheumatol; 2012 Feb 22; 22(1):109-15. PubMed ID: 21667343
    [Abstract] [Full Text] [Related]

  • 16. Intravenous Golimumab in Children With Polyarticular-Course Juvenile Idiopathic Arthritis: Long-Term Extension of an Open-Label Phase III Study.
    Brunner HI, Pacheco-Tena C, Louw I, Vega-Cornejo G, Alexeeva E, Appenzeller S, Chasnyk V, Griffin T, Suarez CN, Knupp-Oliveira S, Zeft A, Aviel YB, De Ranieri D, Gottlieb BS, Levy DM, Rabinovich CE, Silva CA, Spivakovsky Y, Uziel Y, Ringold S, Xu XL, Leu JH, Lam E, Wang Y, Lovell DJ, Martini A, Ruperto N, Pediatric Rheumatology Collaborative Study Group (PRCSG) and Paediatric Rheumatology International Trials Organisation (PRINTO).
    J Rheumatol; 2024 Nov 01; 51(11):1125-1134. PubMed ID: 39089836
    [Abstract] [Full Text] [Related]

  • 17. Tocilizumab (Actemra).
    Sheppard M, Laskou F, Stapleton PP, Hadavi S, Dasgupta B.
    Hum Vaccin Immunother; 2017 Sep 02; 13(9):1972-1988. PubMed ID: 28841363
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Intravenous abatacept in Japanese patients with polyarticular-course juvenile idiopathic arthritis: results from a phase III open-label study.
    Hara R, Umebayashi H, Takei S, Okamoto N, Iwata N, Yamasaki Y, Nakagishi Y, Kizawa T, Kobayashi I, Imagawa T, Kinjo N, Amano N, Takahashi Y, Mori M, Itoh Y, Yokota S.
    Pediatr Rheumatol Online J; 2019 Apr 30; 17(1):17. PubMed ID: 31039807
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.